[go: up one dir, main page]

MX2019006950A - Metodos para tratar la sinaptopatia coclear. - Google Patents

Metodos para tratar la sinaptopatia coclear.

Info

Publication number
MX2019006950A
MX2019006950A MX2019006950A MX2019006950A MX2019006950A MX 2019006950 A MX2019006950 A MX 2019006950A MX 2019006950 A MX2019006950 A MX 2019006950A MX 2019006950 A MX2019006950 A MX 2019006950A MX 2019006950 A MX2019006950 A MX 2019006950A
Authority
MX
Mexico
Prior art keywords
methods
cochlear synaptopathy
treating
treating cochlear
synaptopathy
Prior art date
Application number
MX2019006950A
Other languages
English (en)
Other versions
MX390370B (es
Inventor
Scott Lorrain Daniel
Ming-Yuan Poon Michael
Joy Stebbins Karin
Original Assignee
Pipeline Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pipeline Therapeutics Inc filed Critical Pipeline Therapeutics Inc
Publication of MX2019006950A publication Critical patent/MX2019006950A/es
Publication of MX390370B publication Critical patent/MX390370B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Dental Preparations (AREA)
  • Glass Compositions (AREA)

Abstract

La presente solicitud describe el uso de inhibidores de la gamma secretasa y de modulares de la gamma secretasa para el tratamiento de la sinaptopatía coclear.
MX2019006950A 2016-12-16 2017-12-12 Metodos para tratar la sinaptopatia coclear MX390370B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662435629P 2016-12-16 2016-12-16
US201762515839P 2017-06-06 2017-06-06
PCT/US2017/065892 WO2018111926A2 (en) 2016-12-16 2017-12-12 Methods of treating cochlear synaptopathy

Publications (2)

Publication Number Publication Date
MX2019006950A true MX2019006950A (es) 2019-10-15
MX390370B MX390370B (es) 2025-03-20

Family

ID=62559229

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006950A MX390370B (es) 2016-12-16 2017-12-12 Metodos para tratar la sinaptopatia coclear

Country Status (13)

Country Link
US (2) US10925872B2 (es)
EP (1) EP3554502A4 (es)
JP (1) JP6904612B2 (es)
KR (1) KR20190098998A (es)
CN (1) CN110337291A (es)
AU (1) AU2017376109A1 (es)
CA (1) CA3047096A1 (es)
IL (1) IL267253B2 (es)
MX (1) MX390370B (es)
PH (1) PH12019501373A1 (es)
RU (1) RU2757276C2 (es)
WO (1) WO2018111926A2 (es)
ZA (1) ZA201903873B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2094836B1 (en) 2006-11-15 2016-06-08 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
HK1211875A1 (en) 2012-09-07 2016-06-03 Massachusetts Eye & Ear Infirmary Treating hearing loss
AR105080A1 (es) * 2015-07-07 2017-09-06 Lilly Co Eli Compuestos inhibidores de la señalización de la vía de notch
EP3368515B1 (en) * 2015-10-30 2019-07-17 Inception 3, Inc. Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
EP3407901B1 (en) 2016-01-29 2021-07-21 Massachusetts Eye & Ear Infirmary Expansion and differentiation of inner ear supporting cells and methods of use thereof
PL3846903T3 (pl) 2018-09-03 2024-05-06 F. Hoffmann-La Roche Ag Bicykliczne pochodne heteroarylowe
TW202034900A (zh) 2018-10-02 2020-10-01 美商頻率醫療公司 有關耳用治療劑之醫藥組成物及方法
LT3894411T (lt) 2018-12-13 2024-08-26 F. Hoffmann-La Roche Ag 7-fenoksi-n-(3-azabiciklo[3.2.1]oktan-8-il)-6,7-dihidro-5h-pirolo [1,2-b][1,2,4]triazol-2-amino dariniai ir susiję junginiai kaip gama sekretazės moduliatoriai alzheimerio ligai gydyti
US20220175776A1 (en) 2019-04-08 2022-06-09 Frequency Therapeutics, Inc. Combination of chir99021 and valproic acid for treating hearing loss
US12390510B2 (en) 2019-05-29 2025-08-19 Massachusetts Eye And Ear Infirmary Methods of treating sensorineural hearing loss using fibroblast growth factor 2 (FGF2)

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970705A2 (en) 1996-12-23 1998-10-31 Warren J. Porter CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING "beta" -AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
GB0005251D0 (en) 2000-03-03 2000-04-26 Merck Sharp & Dohme Therapeutic compounds
ES2275657T3 (es) 2000-03-20 2007-06-16 MERCK SHARP & DOHME LTD. Derivados de bicicloalquilo puenteados sulfonamido sustituidos.
GB0008710D0 (en) 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic compounds
CA2427206C (en) 2000-11-02 2011-06-28 Merck Sharp & Dohme Limited Sulfamides as gamma-secretase inhibitors
US6483732B2 (en) 2000-12-13 2002-11-19 Koninklijke Philips Electronics N.V. Relational content addressable memory
GB0119152D0 (en) 2001-08-06 2001-09-26 Merck Sharp & Dohme Therapeutic agents
DE60328182D1 (de) 2002-05-01 2009-08-13 Merck Sharp & Dohme Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase
GB0209991D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0209995D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0209997D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0223039D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223038D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0225474D0 (en) 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
GB0225475D0 (en) 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
BRPI0410348A (pt) 2003-05-14 2006-05-30 Torreypines Therapeutics Inc compostos e usos dos mesmos na modulação de amilóide-beta
GB0318447D0 (en) 2003-08-05 2003-09-10 Merck Sharp & Dohme Therapeutic agents
KR20070087233A (ko) * 2003-09-09 2007-08-27 에프. 호프만-라 로슈 아게 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체
JP2007506715A (ja) 2003-09-24 2007-03-22 メルク シャープ エンド ドーム リミテッド ガンマセクレターゼ阻害剤
HRP20151197T1 (hr) * 2003-10-06 2015-12-04 F. Hoffmann - La Roche Ag Supstituirani derivati dibenzo-azepina i benzo-diazepina, koji su korisni kao inhibitori gama-sekretaze
GB0326039D0 (en) 2003-11-07 2003-12-10 Merck Sharp & Dohme Therapeutic agents
CN101747324A (zh) 2004-07-13 2010-06-23 弗·哈夫曼-拉罗切有限公司 磺酰胺衍生物
EP2198863A1 (en) 2006-02-27 2010-06-23 The Johns Hopkins University Cancer treatment with gamma-secretase inhibitors
AU2008287124B2 (en) 2007-08-14 2013-06-06 Eli Lilly And Company Azepine derivatives as gamma-secretase inhibitors
US8084477B2 (en) 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
CN101909633B (zh) 2008-01-11 2012-05-30 霍夫曼-拉罗奇有限公司 γ-分泌酶抑制剂用于治疗癌症的应用
CA2743436C (en) * 2008-11-24 2017-10-31 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
US8871460B2 (en) * 2009-11-09 2014-10-28 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
CA2884309A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
HK1211875A1 (en) * 2012-09-07 2016-06-03 Massachusetts Eye & Ear Infirmary Treating hearing loss
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
CN103428642B (zh) 2013-07-16 2016-01-13 无锡北邮感知技术产业研究院有限公司 基于中继的簇内d2d多播方法
EP2853533A1 (de) * 2013-09-29 2015-04-01 Audiocure Pharma GmbH 6-Fluor-9-methyl-ß-carbolin
DK3126361T3 (da) 2014-04-01 2020-01-02 Pfizer Chromen og 1,1a,2,7b-tetrahydrocyclopropa[c]chromen- pyridopyrazindioner som gamma-sekretase-modulatorer
US9802927B2 (en) 2015-06-10 2017-10-31 Denali Therapeutics, Inc. Oxadiazine compounds and methods of use thereof
AR105080A1 (es) 2015-07-07 2017-09-06 Lilly Co Eli Compuestos inhibidores de la señalización de la vía de notch
EP3368515B1 (en) * 2015-10-30 2019-07-17 Inception 3, Inc. Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders
US20190022101A1 (en) 2016-01-06 2019-01-24 Massachusetts Eye And Ear Infirmary Treating Cochlear Synaptopathy
US11395606B2 (en) 2016-01-22 2022-07-26 Massachusetts Eye And Ear Infirmary Detecting hidden hearing loss

Also Published As

Publication number Publication date
ZA201903873B (en) 2022-02-23
MX390370B (es) 2025-03-20
PH12019501373A1 (en) 2020-01-20
WO2018111926A3 (en) 2018-07-26
CN110337291A (zh) 2019-10-15
EP3554502A2 (en) 2019-10-23
RU2019122151A (ru) 2021-01-18
RU2757276C2 (ru) 2021-10-12
WO2018111926A2 (en) 2018-06-21
IL267253B (en) 2022-12-01
JP2020503380A (ja) 2020-01-30
IL267253A (en) 2019-08-29
JP6904612B2 (ja) 2021-07-21
US20210196712A1 (en) 2021-07-01
IL267253B2 (en) 2023-04-01
KR20190098998A (ko) 2019-08-23
EP3554502A4 (en) 2021-01-06
US20190307746A1 (en) 2019-10-10
CA3047096A1 (en) 2018-06-21
AU2017376109A1 (en) 2019-07-11
US10925872B2 (en) 2021-02-23
RU2019122151A3 (es) 2021-03-30

Similar Documents

Publication Publication Date Title
MX2019006950A (es) Metodos para tratar la sinaptopatia coclear.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
IL272948A (en) ENPP1 inhibitors and their use for cancer treatment
CO2019001193A2 (es) Métodos y composiciones para el tratamiento de trastornos epilépticos
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
IL270511A (en) Combination therapies using niraparib and pembrolizumab for treating cancer
NZ731467A (en) Anti-tim3 antibodies and methods of use
HRP20180697T1 (hr) Spojevi imidazo[4,5-c]kinolin-2-ona i njihova upotreba za liječenje raka
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
IL271863B (en) Compounds and use thereof for the treatment of microbial infections
MX2018010993A (es) Derivados de icariina e icaritina.
BR112017027721A2 (pt) formulação de alta concentração
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
PL3823623T3 (pl) Podstawiony związek aminopirymidynowy do zastosowania w metodzie leczenia i zapobiegania stwardnieniu rozsianemu
PL3373922T3 (pl) Kompozycje i sposoby do stosowania do leczenia homocystynurii
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1
EP3484474A4 (en) CALMODULIN INHIBITORS, CHK2 INHIBITORS AND RSK INHIBITORS FOR THE TREATMENT OF RIBOSOME DISORDERS AND RIBOSOMOPATHIES
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.